News
Tower Mains Weekly Newsletter 18th May 2022
Tower Mains Weekly Newsletter Company Updates WHO and MPP announce agreement with NIH for COVID-19 health technologies On 12th May, the World Health Organisation’s COVID-19 Technology Access Pool (C-TAP) and [...]
GMP / GDP Career Opportunities
GMP / GDP Career Opportunities at Tower Mains Tower Mains is growing, and we are on the lookout for QA professionals to strengthen our GMP / GDP team! Are you [...]
Tower Mains Weekly Newsletter 11th May 2022
Tower Mains Weekly Newsletter Company Updates Tower Mains is delighted to welcome Olga Pavlovska as Senior Associate. Olga will be providing clinical quality assurance support to our clients. We are exhibiting at [...]
Tower Mains is delighted to welcome Olga Pavlovska
Tower Mains is delighted to welcome Olga Pavlovska as Senior Associate. Hailing from Kyiv, Olga graduated from Bogomolets National Medical University in Ukraine with a specialism in epidemiology and began her career [...]
Tower Mains Weekly Newsletter 4th May 2022
Tower Mains Weekly Newsletter Industry Updates FDA approves first device indicated for the preservation of donation-after-circulatory-death hearts On 27th April, the US Food and Drug Administration (FDA) approved an expanded [...]
Tower Mains Weekly Newsletter 27th April 2022
Tower Mains Weekly Newsletter Industry Updates FDA publishes guidance on the development of drug products including those that contain nanomaterials On 21st April, the US Food and Drug Administration (FDA) [...]
Tower Mains Weekly Newsletter 20th April 2022
Tower Mains Weekly Newsletter Industry Updates FDA authorises first COVID-19 diagnostic test using breath samples On 14th April, the US Food and Drug Administration (FDA) issued an emergency use authorisation [...]
MHRA Compliance Monitoring Scheme
MHRA Compliance Monitoring Scheme: Step in the right direction or first on a slippery slope? From April 2022, the MHRA will begin a pilot programme for GMP and GDP remediation [...]
Tower Mains Weekly Newsletter 13th April 2022
Tower Mains Weekly Newsletter Industry Updates ECDC and EMA conclude it’s too early to consider using a fourth dose of mRNA COVID-19 vaccines On 6th April, the European Centre for [...]
Meet the Team – Q&A with Senior Associate Naomi Ervine
Meet the Team – Q&A with Senior Associate Naomi Ervine Having worked within Quality Assurance (QA) in the pharmaceutical industry for the last 14 years, Naomi joined Tower Mains in [...]
